Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort [Phase 1]
The update announces the completion of a Phase 1 trial of PTX-100 in patients with advanced malignancies, including a PTCL expansion cohort.
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL [Phase 1]
A Phase 1 clinical trial is investigating a CD7-targeted CAR-T therapy for relapsed/refractory peripheral T-cell lymphoma and is currently r…
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating the combination of linperlisib with chidamide for relapsed or refractory peripheral T-cell lymph…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma [EARLY_Phase 1]
An early-phase 1 trial evaluating chemoimmunotherapy followed by an allogeneic stem cell transplant for natural killer cell lymphoma/leukemi…
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. [Phase 2]
Phase 2 trial evaluating a triplet regimen of golidocitinib with azacitidine and chidamide in peripheral T-cell lymphoma; the study is not y…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-07-22Clinical Trial Update: Polyspecific Antibodies in Lymphoproliferative T-cell Disorders [Phase 1, Phase 2]
A Phase 1/2 clinical trial of polyspecific antibodies for peripheral T-cell lymphoma is currently recruiting, sponsored by Xenothera SAS.
-
CLINICAL_TRIALS research · 2025-07-20Clinical Trial Update: Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients [NA]
A clinical trial evaluating chidamide in combination with Brentuximab Vedotin for CD30-positive peripheral T-cell lymphoma is currently recr…
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients [NA]
This clinical trial update reports a triplet regimen of bendamustine, chidamide, and lenalidomide for relapsed and refractory peripheral T-c…
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of duvelisib and venetoclax in relapsed or refractory peripheral T-cell lymphoma, w…
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) [Phase 2]
A Phase 2 trial of Brentuximab vedotin in combination with CHP for CD30-positive Peripheral T-Cell Lymphoma in Chinese participants is curre…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System [Phase 1]
Phase 1 trial investigating safety and activity of a novel TNFR2 inhibitor in adults with non-Hodgkin lymphoma, including cutaneous T-cell l…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) [Phase 2]
A Phase 2 clinical trial evaluating the oral JAK1 inhibitor golidocitinib in newly diagnosed Peripheral T-cell lymphoma is not yet recruitin…
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CD5-targeted CAR T-cell therapy for relapsed/refractory T-cell lymphomas is currently recruiting in Be…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: Expanded Access to Tipifarnib
Kura Oncology announced expanded access to Tipifarnib for patients with HRAS mutations or Peripheral T-Cell Lymphoma.
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL [Phase 3]
This Phase 3 clinical trial compares mitoxantrone hydrochloride liposome injection to chidamide in patients with relapsed/refractory periphe…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: GVM±R in Patients With Relapsed or Refractory Aggressive NHL. [Phase 2]
Phase 2 clinical trial update for GVM±R in adults with relapsed or refractory aggressive non-Hodgkin lymphoma, including Peripheral T-cell l…
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating CD7-directed CAR T-cell therapy for relapsed/refractory T-cell lymphomas (including PTCL and CTC…
-
CLINICAL_TRIALS research · 2025-05-09Clinical Trial Update: A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma
A real-world study evaluating regimens based on golidocitinib for peripheral T-cell lymphoma is not yet recruiting, sponsored by Ruijin Hosp…
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
This is an international prospective registry enrolling patients with newly diagnosed Peripheral T-Cell Lymphoma to collect observational da…
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies [Phase 1]
This clinical trial update describes a Phase 1 dose-escalation and dose-expansion study of anti-CD7 allogeneic CAR T-cells (WU-CART-007) in …
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies [Phase 1]
A Phase 1 clinical study evaluating the CD70-targeted agent CHT101 in relapsed or refractory hematologic malignancies is currently recruitin…
-
CLINICAL_TRIALS research · 2025-03-11Clinical Trial Update: Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) [Phase 2]
A phase 2 clinical trial evaluating chidamide for relapsed or refractory peripheral T-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL [Phase 1, Phase 2]
This document reports a Phase I/II clinical trial evaluating golidocitinib in combination with pomalidomide for relapsed/refractory peripher…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial update for BP1002 in advanced lymphoid malignancies across several B-cell and T-cell lymphomas; trial status is activ…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma [Phase 2]
A Phase 2 clinical trial combining chidamide with duvelisib for relapsed or refractory peripheral T-cell lymphoma is currently recruiting.